Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer

Fig. 3

Regorafenib 10 mg/kg/day inhibits tumor angiogenesis and tumor cell proliferation, and induces apoptosis. The effects of regorafenib on tumor angiogenesis (CD31 expression), cell proliferation (p-Ser10 histone H3 expression), and apoptosis (cleaved PARP expression) are demonstrated in xenografts GC17-0409 (diffuse histology; a), GC28-1107 (more intestinal; b), and GC09-0109 (tubular histology; c). Dotted lines denote areas of necrosis. PARP: poly(ADP ribose) polymerase

Back to article page